Related Experiment Video

Updated: Jul 5, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

[Effects of antiosteoporotic agents on glucose and lipid metabolism and cardiovascular system]

Shiho Fukai1

  • 1The University of Tokyo, Graduate School of Medicine, Department of Geriatric Medicine.

Clinical Calcium
|May 1, 2008
PubMed

Insights

Postmenopausal women face high cardiovascular disease risks. While Hormone Replacement Therapy (HRT) shows mixed results for coronary artery disease (CAD), Vitamin D may offer vascular protection.

Area of Science:

  • Endocrinology and Cardiovascular Medicine
  • Focuses on hormonal influences and vascular health in postmenopausal women.

Context:

  • Cardiovascular disease (CVD) is a leading cause of death in postmenopausal women.
  • Hormone Replacement Therapy (HRT) has demonstrated positive effects on metabolic and vascular markers.
  • However, clinical trials present conflicting data regarding HRT's efficacy in preventing coronary artery disease (CAD).

Purpose:

  • To evaluate the role of Vitamin D in cardiovascular health for postmenopausal women.
  • To compare the potential benefits of Vitamin D against established therapies like HRT and selective estrogen receptor modulators (SERMs).

Summary:

  • Randomized trials question HRT's effectiveness in primary and secondary CAD prevention, despite its lipid-lowering properties.
  • Selective estrogen receptor modulators (SERMs) show a neutral effect on CAD and stroke but increase venous thromboembolic risks.
  • Emerging evidence suggests Vitamin D enhances vascular compliance and reduces inflammation, potentially improving survival rates.

Impact:

  • Highlights Vitamin D as a potential therapeutic agent for cardiovascular risk reduction in postmenopausal women.
  • Suggests a shift towards exploring non-hormonal interventions for managing cardiovascular health in this demographic.
  • Provides a basis for further research into Vitamin D's mechanisms in vascular protection.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...